-
Customers success stories
Hybridoma-based antibody development: Targeting Long QT Syndrome and Advancing Cardiac Research
At ProteoGenix, we are always ready to take on a challenge. Particularly when it involves helping you reach your objectives. In this article, we will present you another success story…
-
Antibody production
How are mouse monoclonal antibodies humanized: current approaches and limitations
Read more -
Blog
Humanized vs. Fully Human Antibodies: What’s the Difference?
Read more -
Antibody production
Antibody production: a complete guide
Read more -
Antibody production
Phage Display vs. Hybridoma: Choosing the Right Method for Monoclonal Antibody Production
Read more -
Antibody-drug conjugates
Therapeutic ADCs: mechanisms of action and advantages
Read more
-
Antibody-drug conjugates
Everything you need to know about the generation of antibody-drug conjugates (ADCs)
Read more -
CAR-T cell therapy
CAR-T cell engineering: strategies to overcome remaining limitations
Read more -
Antibody production
Fundamental and advanced methods to improve monoclonal antibody production in vitro
Read more -
Antibody production
The untapped potential of bispecific antibody therapies
Read more -
Antibody production
What are the leading monoclonal antibody treatments for cancer?
Read more
-
Antibody production
“The COVID-19 pandemic is helping us bridge the divide between virologists and immunologists” – Interview with Dr. Louisa James (QMUL)
Read more -
Antibody production
Reinventing IgY biotherapeutics – interview with Dr. Mara Freire (CICECO, University of Aveiro, Portugal)
Read more -
Antibody production
How the environment shapes immune system development during pregnancy – interview with Dr. Melanie Conrad
Read more -
Antibody production
“Cell-based phage display is helping us isolate more biologically relevant antibodies” – Interview with Dr. Mohamed Alfaleh (King Abdulaziz University)
Read more -
Antibody production
“Researchers are not leveraging the speed and resolution of flow cytometry for clinical evaluation” – Interview with Prof. Tomáš Kalina (Charles University in Prague)
Read more